Tsubota Laboratory Incorporated Logo

Tsubota Laboratory Incorporated

R&D company developing treatments for ophthalmology and CNS disorders.

4890 | T

Overview

Corporate Details

ISIN(s):
JP3535700003
LEI:
Country:
Japan
Address:
新宿区信濃町35 慶應義塾大学信濃町キャンパス2号館9階CRIK信濃町E7

Description

Tsubota Laboratory Incorporated is a research and development company that originated as a startup from Keio University. It is engaged in the creation of pharmaceuticals and medical devices. The company's primary focus is on ophthalmology, developing solutions for conditions such as myopia, dry eye, and presbyopia. Additionally, it explores treatments for central nervous system (CNS) disorders and brain diseases. The corporate strategy centers on out-licensing its developed pipelines to commercial partners. A notable pipeline is a therapeutic candidate designed to curtail the progression of myopia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 07:34
確認書
Japanese 9.0 KB
2025-11-12 07:33
半期報告書-第14期(2025/04/01-2026/03/31)
Japanese 195.3 KB
2025-06-27 04:35
臨時報告書
Japanese 23.3 KB
2025-06-26 09:02
確認書
Japanese 9.4 KB
2025-06-26 09:01
内部統制報告書-第13期(2024/04/01-2025/03/31)
Japanese 23.5 KB
2025-06-26 09:01
有価証券報告書-第13期(2024/04/01-2025/03/31)
Japanese 1.6 MB
2024-11-14 08:02
確認書
Japanese 9.0 KB
2024-11-14 08:02
半期報告書-第13期(2024/04/01-2025/03/31)
Japanese 201.7 KB
2024-06-27 04:10
内部統制報告書-第12期(2023/04/01-2024/03/31)
Japanese 22.8 KB
2024-06-27 04:09
確認書
Japanese 8.9 KB
2024-06-27 04:08
有価証券報告書-第12期(2023/04/01-2024/03/31)
Japanese 1.7 MB
2024-02-14 07:11
確認書
Japanese 9.0 KB
2024-02-14 07:10
四半期報告書-第12期第3四半期(2023/10/01-2023/12/31)
Japanese 160.1 KB
2023-11-13 07:06
確認書
Japanese 9.0 KB
2023-11-13 07:02
四半期報告書-第12期第2四半期(2023/07/01-2023/09/30)
Japanese 193.0 KB

Automate Your Workflow. Get a real-time feed of all Tsubota Laboratory Incorporated filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Tsubota Laboratory Incorporated

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Tsubota Laboratory Incorporated via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Avalo Therapeutics, Inc. Logo
Clinical-stage biotech developing treatments for immune-mediated inflammatory diseases.
United States of America
AVTX
Azenta, Inc. Logo
Offers sample management, storage, and multiomics solutions for life sciences.
United States of America
AZTA
BenevolentAI Logo
Applies artificial intelligence to accelerate drug discovery and development.
United Kingdom
BAI
bioAffinity Technologies, Inc. Logo
Develops noninvasive diagnostics and targeted therapeutics for cancer.
United States of America
BIAF
BioArctic Logo
Biopharmaceutical firm developing antibody therapies for neurodegenerative diseases.
Sweden
BIOA
BioInfra Co.,Ltd. Logo
Develops multi-biomarker blood tests for early cancer screening and gene treatments.
South Korea
199730
BioInfra Life Science Inc. Logo
Develops multi-biomarker blood tests for early cancer screening and gene treatments.
South Korea
266470
BioNexus Gene Lab Corp Logo
Develops gene-based diagnostics for early detection of disease susceptibility.
United States of America
BGLC
Biophytis S.A. Logo
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
France
ALBPS
BioRestorative Therapies, Inc. Logo
Develops adult stem cell therapies for degenerative disc and metabolic disorders.
United States of America
BRTX

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.